Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737693 | 0.77 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8737210 | 0.69 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8737148 | 0.69 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8737804 | 0.68 | MAOA (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13362405 | 0.66 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8737174 | 0.65 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8737186 | 0.64 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8737202 | 0.63 | PSEN1 (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8737370 | 0.62 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8737197 | 0.60 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| WO-2010054067-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 8/4885APH1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.